As coronavirus disease 2019 (COVID-19) continues its deadly sweep across the globe, the role of extracorporeal membrane oxygenation (ECMO) in the management of severely ill patients with COVID-19 who have developed acute respiratory symptoms continues to increase.
As of August 20, 2020, the global population of COVID-19 patients supported with ECMO stood at 2285, 55% (89 of 1604) of whom were discharged home alive. Most of the COVID-19 patients treated with ECMO (1464) were in North America with 541 in Europe, 48 in the Asia Pacific and 104 in Latin America.
The increasing number of COVID-19 patients being treated with ECMO is propelling inquiries from every corner of the globe about how the ELSA Monitor provides clinicians with vital quantitative information to maximize ECMO efficiency.
Not only can oxygenator clotting be quantified with the ELSA Monitor to quantify early oxygenator clot formation and create a wider window of opportunity to perform oxygenator change-outs when needed,
but the percentage recirculation can be quantified. Knowing recirculation helps an intensivist adjust cannula position and pump flow to optimize treatment as well as identify low cardiac output due to hypovolemia or heart failure. Clinicians also learn that by knowing actual delivered flow they can verify circuit flows, determine flows in bridges or shunts, determine the optimal pump flow setting for any cannula or configuration, and identify tubing flow restrictions that might cause hemolysis or increase pressure within the circuit.
For more information about the ELSA Monitor, contact Sierra Coyle at firstname.lastname@example.org.